Downloadable Slides with Notes

Share

Program Content

Activities

  • Integrating Oral SERDs: HR+/HER2- BC
    Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need $100.00
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 13, 2024

    Expires: November 12, 2025

  • Sequencing Oral SERDs: HR+/HER2- BC
    Sequencing Novel SERDs in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 15, 2024

    Expires: November 14, 2025

  • Managing Oral SERD Related AEs in HR+/HER2- MBC
    Managing AEs With Oral SERDs for Patients With HR+/HER2- Metastatic Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 15, 2024

    Expires: November 14, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Lilly

AstraZeneca

Lilly